Ipsen stock | Price, analyst rating, price target & growth

Ipsen

ENXTPA:IPN

€ 167,50

€0,00 (0,00%)

167,50 €

€0,00 (0,00%)

End-of-day quote: 04/03/2026

Ipsen Stock Value

Analysts currently give Ipsen a rating of Outperform.

Outperform

Ipsen Company Info

EPS Growth 5Y

10,59%

Market Cap

€13,75 B

Long-Term Debt

€0,83 B

Annual earnings

N/A

Dividend

€1,41

Dividend Yield

0,84%

Founded

1929

Industry

Health Care

Country

France

Website

Ipsen

ISIN Number

FR0010259150

Website

http://www.ipsen.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

€155,00

-7.46%

Last Update: 04/04/2026

Analysts: 16

Highest Price Target €175,00

Average Price Target €155,00

Lowest Price Target €117,00

In the last five quarters, Ipsen’s Price Target has risen from €107,26 to €128,13 - a 19,46% increase. Eight analysts predict that Ipsen’s share price will fall in the coming year, reaching €155,00. This would represent a decrease of -7,46%.

Top growth stocks in the health care sector (5Y.)

What does Ipsen do?

Ipsen S.A. operates as a global biopharmaceutical group dedicated to the development of innovative medicines that meet the critical medical needs of patients around the world. The company is known for its focus on specialty care, particularly in areas such as oncology, neuroscience, and rare diseases. It strives to create value by combining a robust pipeline of therapeutic candidates with established products, thereby offering a diverse portfolio to healthcare professionals and patients alike....

Ipsen S.A. operates as a global biopharmaceutical group dedicated to the development of innovative medicines that meet the critical medical needs of patients around the world.

The company is known for its focus on specialty care, particularly in areas such as oncology, neuroscience, and rare diseases. It strives to create value by combining a robust pipeline of therapeutic candidates with established products, thereby offering a diverse portfolio to healthcare professionals and patients alike.

Business Segments

The company is organized into several distinct business segments that primarily include pharmaceuticals and biologics. The company’s pharmaceutical segment focuses on the research, development, and commercialization of innovative therapeutics, mainly in oncology and rare diseases. It includes well-established products alongside emerging therapies.

In the oncology space, the company has developed products like Cabometyx, which has showcased solid performance due to its efficacy and safety profile, and Onivyde, known for its role in treating specific forms of cancer. Within the realm of rare diseases, the company's recent acquisition of Albireo Pharmaceuticals has enhanced its offerings, adding Bylvay, a therapeutic agent for patients with Alagille syndrome, to its product lineup.

The company also has a prominent position in the neurosciences market with Dysport, a botulinum toxin product utilized for both therapeutic and aesthetic applications. Dysport's performance has been particularly strong in aesthetics, revealing a growing demand among patients looking for cosmetic solutions.

Along with these prominent therapeutic areas, the company continuously invests in its research and development pipelines, ensuring that its segments remain robust and competitive in the biopharmaceutical landscape. This holistic approach to segment operations enables the company to maintain a diverse yet focused portfolio, giving the company an advantage in delivering innovative treatment options globally.

Business Strategy

The company has outlined a comprehensive business strategy aimed at facilitating sustained growth while delivering significant value to patients and shareholders. The company's recent roadmap is anchored on a multi-faceted approach to business development. This strategy encompasses the expansion of its therapeutic lines through both internal development and external innovation avenues.

Core to the strategy is an active engagement in scientific advancements and clinical research focusing on breakthrough therapies that address significant unmet medical needs. The company aims to propel its pipeline of near-term launches, combined with anticipated mid-term milestones, to strengthen its market presence in specialty care.

Sustainability is another pillar supporting the company’s strategy, encapsulated under its Generation the company initiative. The company has committed itself to reducing greenhouse gas emissions and has articulated its ambition to achieve carbon neutrality by 2025. In 2023, the company documented significant reductions in its Scope 1, 2, and 3 emissions, highlighting its adherence to environmentally responsible business practices.

Furthermore, the company places significant emphasis on enhancing operational efficiencies and optimizing its capital allocation.

Products and Services

The company delivers an extensive array of products and services, predominantly revolving around innovative therapeutics that cater to a plethora of medical needs. The company's offerings can be categorized into various therapeutic areas, with a strong emphasis on oncology, neurosciences, and rare diseases.

Among the core products, Cabometyx stands out as a leading therapy for renal cell carcinoma and hepatocellular carcinoma. The company continues to support its usage through educational initiatives and engagement with healthcare providers to ensure optimal patient outcomes.

Dysport is another flagship product, renowned for its uses in both therapeutic and aesthetic procedures. It has gained traction in various therapeutic domains including the treatment of muscle spasticity and overactive bladder, alongside its aesthetic applications in wrinkle reduction.

The recent addition of Bylvay into the product portfolio significantly enhances the company's capabilities in treating Alagille syndrome in pediatric patients, reflecting the company's commitment to addressing rare diseases effectively.

Geographical Markets Served

The company operates in various global markets, including North America, Europe, and the Rest of the World. The geographical expansion is a focal point of the company’s strategic initiatives. The North American market has experienced notable growth, driven by strong performance from key drugs like Onivyde and Bylvay, alongside Dysport and Cabometyx.

In Europe, the company’s sales performance has shown staunch stability, with careful management of both established products and newly launched therapies contributing to its overall market strength. The company’s robust pipeline and recent acquisitions significantly bolster its competitive position across geographies.

The strategic acquisition of Albireo Pharmaceuticals in March 2023 has allowed the company to diversify further and strengthen its product offerings in rare diseases. This move is indicative of the company’s commitment to enhancing its therapeutic spectrum and providing advanced solutions to underserved patient populations.

Seasonality

Typically, quarterly fluctuations may arise due to factors such as product launches, market cycles, competitive dynamics, and emotional buying patterns associated with therapeutic products.

For instance, products in the aesthetics domain, such as Dysport, may witness heightened demand during seasonal occasions where individuals seek cosmetic enhancements. While these seasonal trends may create variations, overall performance is designed to deliver consistent value across its annual cycles.

Customers

The company serves a diverse customer base, predominantly comprising healthcare professionals, hospitals, and specialty clinics across different geographical markets. The customer categories include oncologists, neurologists, general practitioners, and rare disease specialists who leverage the company's offerings in clinical settings.

Modes of Sales and Marketing, Distribution Channels

The company employs a multifaceted sales and marketing strategy to effectively distribute its products. The company utilizes a direct sales force specialized in various therapeutic areas, ensuring that healthcare providers receive updated product information and support.

Additionally, the company engages in partnerships with distributors and healthcare organizations to broaden its reach and enhance the availability of its products. This collaborative approach empowers the company to penetrate diverse markets and ensure that patients have access to its innovative therapies.

Digital marketing strategies play a vital role in the company’s outreach programs, involving online platforms for educational content, seminars, and webinars tailored to healthcare providers. This focus on digital engagement reflects the company's evolving approach to marketing in the modern healthcare landscape.

Government Regulations

The company operates under stringent regulatory frameworks governing the biopharmaceutical industry. Compliance with regulations set forth by authorities such as the FDA and EMA is critical in ensuring that products meet safety and efficacy standards before reaching patients.

History

Ipsen S.A. was founded in founded in 1929. The company was incorporated in 1998.

Ipsen Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 100% (2025) **TOP 3 Markets:** 1. **USA:** approx. 35% 2. **Europe (excluding France):** approx. 30% 3. **France:** approx. 15% Ipsen S.A. is a globally active biopharmaceutical company that focuses on specialty medicines. The company's entire revenue comes from the...

At which locations are the company’s products manufactured?

**Production sites of Ipsen S.A.:** 1. **France:** Ipsen has several production facilities in France, including in Dreux and Signes. 2. **Ireland:** A significant production site is located in Dublin. 3. **China:** Ipsen also operates a production plant in Wuxi. Ipsen S.A. is a globally active pha...

What strategy does Ipsen pursue for future growth?

**Revenue Growth:** Estimated 6-8% annually (2025 forecast) **Focus on R&D Investments:** 20% of revenue (2024) Ipsen S.A. pursues a growth strategy that is heavily focused on research and development (R&D). The company invests approximately 20% of its revenue in R&D to expand its pip...

Which raw materials are imported and from which countries?

**Main raw materials:** Peptides, organic chemicals, pharmaceutical active ingredients **Import countries:** USA, China, India, Germany Ipsen S.A. is a globally operating pharmaceutical company that relies on a variety of raw materials for the production of its products. The most important materia...

How strong is the company’s competitive advantage?

**Market share in the oncology segment:** 10% (2024, estimated) **R&D expenses:** 20% of revenue (2023) **Patent portfolio:** 150 active patents (2023) Ipsen S.A. has a significant competitive advantage, especially in the field of oncology, where the company holds an estimated market share...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approximately 60% (2025, estimated) **Insider Buys/Sells:** No significant transactions in the last year (2025, estimated) The institutional investor share at Ipsen S.A. is around 60%, which is typical for a company of this size and industry. Institutional investo...

What percentage market share does Ipsen have?

**Market share of Ipsen S.A.:** Estimate: 3-5% (2025) **Main competitors and their market shares:** 1. **Pfizer Inc.:** 10-12% 2. **Roche Holding AG:** 9-11% 3. **Novartis AG:** 8-10% 4. **Sanofi S.A.:** 7-9% 5. **Johnson & Johnson:** 6-8% 6. **Merck & Co., Inc.:** 5-7% 7. **AstraZeneca plc...

Is Ipsen stock currently a good investment?

**Revenue Growth:** 8.5% (2024) **Research and Development Ratio:** 15% of revenue (2024) **Net Income Growth:** 10% (2024) Ipsen S.A. recorded solid revenue growth of 8.5% in 2024, attributed to a strong product pipeline and successful market launches. The company continues to heavily invest in re...

Does Ipsen pay a dividend – and how reliable is the payout?

**Dividend Yield:** 2.5% (2024) **Dividend History:** Continuous payout over the last 5 years Ipsen S.A. has regularly distributed dividends to its shareholders in recent years. The dividend yield was last around 2.5%, which is competitive compared to other companies in the pharmaceutical industry...

New support ticket

Explore

Ipsen Stock Value

Ipsen Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Ipsen do?

Ipsen Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Ipsen Stock Value

Ipsen Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Ipsen do?

Ipsen Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.